A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

09/11/2015 - 2 minutes

Approved drugs can always show bad signs once injected massively. Four physicians from Paris sent a letter to the New England Journal of Medicine to report that Gilead’s Hepatitis C blockbuster drug, Sovaldi, can cause abnormally slower heart rates and risks of Heart Failure…

Gilead_Sciences_Logo.svgThe French Physicians report used data based on 415 patients treated with the drug in 2014. Three of these patients showed abnormally slow heartbeats (bradycardia). The doctor’s immediately implanted pacemakers to ensure a normal heartbeat was resumed. This a low number of patients regarding to the total of patients treated overall, but the Doctors recommended caution and closer monitoring of cardiac activity in treated patients whilst administering the drug.

This is not the first warning. The FDA released a warning the Hepatitis C drugs could have side effects when taking in conjunction with another drug. Indeed, of the 9 patients taking Solvaldi (or Horvani) in conjunction with heart drug amiodarone, 1 actually died with another 3 afterwards needing pacemakers to correct the bradycardia in May.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member